A Message from VGXI Regarding the Coronavirus (COVID-19) Outbreak and VGXI Actions LAST UPDATED October 01, 2021 To our Valued Clients and Business Partners, VGXI recognizes your concerns regarding the potential impact of the coronavirus outbreak on our products and services. VGXI is actively monitoring the situation and will continue to provide… Read More »
Texas-based plasmid DNA manufacturer VGXI, Inc. recognized as a finalist for Best CMO for the ViE Awards of the World Vaccine Congress The Woodlands, TX – VGXI, Inc., a uniquely specialized CDMO providing high quality plasmid DNA-based products and services, announced it has been nominated as a finalist in the category of… Read More »
The 4th Annual Gene Therapy for Rare Disorders will focus on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. Visit VGXI at Booth #6 or meet with one of our representatives during the conference to learn more about how our plasmid manufacturing services can support your gene… Read More »
The World Vaccine Congress is a critical strategic partnering event for the global vaccine industry. Visit our Booth #310 or meet with a representative from VGXI during the conference in April to learn more about how our plasmid manufacturing services can support your vaccine program! Each year at WVC the winners are announced… Read More »
Texas-based plasmid DNA Manufacturer VGXI, Inc. to Enable Accelerated Production of a Vaccine against the 2019 Novel Coronavirus in a CEPI Funded Collaboration The Woodlands, TX – VGXI, a world leading contract manufacturer of clinical grade DNA plasmid, announced it will start production of a DNA vaccine against the novel coronavirus (2019-nCoV)… Read More »
Under a Technology License Agreement with the Houston Methodist Research Institute, Contract Developer and Manufacturer VGXI Achieves Key Milestones with Establishment of Pilot Production Capabilities for RNA-Based Medicines. The Woodlands, TX – VGXI announces successful implementation of new RNA production services through completion of all Phase II initiatives as part of a… Read More »
Plasmid DNA Manufacturer VGXI, Inc. Selects BE&K Building Group as its Design-Build Partner for the Initial Phase of its New and Expanded Manufacturing Facility December 3, 2019, The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services… Read More »
The ISV Annual Congress is the world’s largest scientific conference in the field of vaccines and covers a broad range of topics related to vaccines and immunotherapies. We welcome you to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn more about VGXI’s plasmid manufacturing… Read More »
The 26th International Symposium on Hepatitis C Virus and Related Viruses focuses on the advancement of HCV and related virus research, vaccines, and therapies. We welcome you to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn more about VGXI’s plasmid manufacturing services and experience!… Read More »
The Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. Be sure to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn how VGXI’s… Read More »
Industry recognized plasmid DNA manufacturer VGXI, Inc. to support production of personalized cancer therapies as part of a long-term supply agreement with Geneos Therapeutics. June 22, 2019, The Woodlands, TX and Plymouth Meeting, PA – Plasmid CMO VGXI, Inc. and Geneos Therapeutics, Inc., a spin-out of Inovio Pharmaceuticals (NASDAQ: INO) focused on developing… Read More »
A new and completely redesigned website offers visitors a comprehensive overview of VGXI’s range of plasmid DNA manufacturing services and capabilities. May 20, 2019, The Woodlands, TX – Texas based CMO VGXI, Inc., which specializes in production of DNA plasmid biopharmaceuticals, announced it has gone live with a refreshed website and online… Read More »
With over 16,000 attendees, BIO is one of the largest biotech partnering, education, and networking events in the world. Be sure to stop by VGXI’s Booth #3349 or schedule a meeting with one of our representatives during the conference to learn how VGXI’s plasmid manufacturing services can support your gene or cell therapy program! Contact Us directly… Read More »